Evidence map›Paper›PMID 36015285›Full record

ArticlePharmaceutics2022

PSME4 Degrades Acetylated YAP1 in the Nucleus of Mesenchymal Stem Cells.

Yong Sook Kim, Mira Kim, Dong Im Cho, Soo Yeon Lim, Ju Hee Jun, Mi Ra Kim, Bo Gyeong Kang, Gwang Hyeon Eom, Gaeun Kang, Somy Yoon and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. PSME4 determines mesenchymal stem cell fate towards cardiac commitment through YAP1 degradation.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yong Sook KimBiomedical Research Institute, Chonnam National University Hospital, Gwangju 61469, Korea.
Mira KimDepartment of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Korea.
Dong Im ChoBiomedical Research Institute, Chonnam National University Hospital, Gwangju 61469, Korea.
Soo Yeon LimBiomedical Research Institute, Chonnam National University Hospital, Gwangju 61469, Korea.
Ju Hee JunBiomedical Research Institute, Chonnam National University Hospital, Gwangju 61469, Korea.
Mi Ra KimBiomedical Research Institute, Chonnam National University Hospital, Gwangju 61469, Korea.
Bo Gyeong KangBiomedical Research Institute, Chonnam National University Hospital, Gwangju 61469, Korea.
Gwang Hyeon EomDepartment of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Korea.ORCID 0000-0002-7904-8503
Gaeun KangDivision of Clinical Pharmacology, Chonnam National University Hospital, Gwangju 61469, Korea.
Somy YoonCollege of Pharmacy, Chonnam National University, Gwangju 61186, Korea.
Youngkeun AhnDepartment of Cardiology, Chonnam National University Hospital, Gwangju 61469, Korea.
Chonnam National University Hospital · KRChonnam National University · KRChonnam National University Hwasun Hospital · KR

Funding

Korea Health Technology R&D Project, Ministry of Health, Welfare HI18C1352National Research Foundation of Republic of Korea 2019R1A2C2010884National Research Foundation of Republic of Korea 2019R1A2C3003547
6 · The paper itself

Abstract

Intensive research has focused on minimizing the infarct area and stimulating endogenous regeneration after myocardial infarction. Our group previously elucidated that apicidin, a histone deacetylase (HDAC) inhibitor, robustly accelerates the cardiac commitment of naïve mesenchymal stem cells (MSCs) through acute loss of YAP1. Here, we propose the novel regulation of YAP1 in MSCs. We found that acute loss of YAP1 after apicidin treatment resulted in the mixed effects of transcriptional arrest and proteasomal degradation. Subcellular fractionation revealed that YAP1 was primarily localized in the cytoplasm. YAP1 was acutely relocalized into the nucleus and underwent proteasomal degradation. Interestingly, phosphor-S127 YAP1 was shuttled into the nucleus, suggesting that a mechanism other than phosphorylation governed the subcellular localization of YAP1. Apicidin successfully induced acetylation and subsequent dissociation of YAP1 from 14-3-3, an essential molecule for cytoplasmic restriction. HDAC6 regulated both acetylation and subcellular localization of YAP1. An acetylation-dead mutant of YAP1 retarded nuclear redistribution upon apicidin treatment. We failed to acquire convincing evidence for polyubiquitination-dependent degradation of YAP1, suggesting that a polyubiquitination-independent regulator determined YAP1 fate. Nuclear PSME4, a subunit of the 26 S proteasome, recognized and degraded acetyl YAP1 in the nucleus. MSCs from PSME4-null mice were injected into infarcted heart, and aberrant sudden death was observed. Injection of immortalized human MSCs after knocking down PSME4 failed to improve either cardiac function or the fibrotic scar area. Our data suggest that acetylation-dependent proteasome subunit PSME4 clears acetyl-YAP1 in response to apicidin treatment in the nucleus of MSCs.

Indexed as

acetylationmesenchymal stem cellPSME4YAP1

Identifiers

PMID36015285
PMCPMC9415559
OpenAlexW4293514279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.